NO20074497L - Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel - Google Patents

Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel

Info

Publication number
NO20074497L
NO20074497L NO20074497A NO20074497A NO20074497L NO 20074497 L NO20074497 L NO 20074497L NO 20074497 A NO20074497 A NO 20074497A NO 20074497 A NO20074497 A NO 20074497A NO 20074497 L NO20074497 L NO 20074497L
Authority
NO
Norway
Prior art keywords
xolair
omalizumab
immunosuppressant
synergistic combination
pharmaceutically acceptable
Prior art date
Application number
NO20074497A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20074497L publication Critical patent/NO20074497L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sammendrag Den foreliggende oppfinnelsen tilveiebringer en farmasøytisk sammensetning omfattende et anti-lgE antistoff og minst et ytterligere immunundertrykkende middel, hvor de aktive ingrediensene er tilstede i hvert tilfelle i fri form eller i formen av et farmasøytisk akseptabelt salt og eventuelt minst en farmasøytisk akseptabel bærer; for samtidig, separat eller sekvensiell anvendelse.
NO20074497A 2005-02-04 2007-09-04 Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel NO20074497L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502358.5A GB0502358D0 (en) 2005-02-04 2005-02-04 Organic compounds
PCT/EP2006/000911 WO2006082052A1 (en) 2005-02-04 2006-02-02 Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent

Publications (1)

Publication Number Publication Date
NO20074497L true NO20074497L (no) 2007-10-26

Family

ID=34355808

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074497A NO20074497L (no) 2005-02-04 2007-09-04 Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel

Country Status (20)

Country Link
US (1) US20080206237A1 (no)
EP (1) EP1846031A1 (no)
JP (1) JP2008528650A (no)
KR (1) KR20070100344A (no)
CN (1) CN101111265A (no)
AR (1) AR053541A1 (no)
AU (1) AU2006210098A1 (no)
BR (1) BRPI0607349A2 (no)
CA (1) CA2595976A1 (no)
GB (1) GB0502358D0 (no)
GT (1) GT200600023A (no)
IL (1) IL184713A0 (no)
MA (1) MA29273B1 (no)
MX (1) MX2007009436A (no)
NO (1) NO20074497L (no)
PE (1) PE20061203A1 (no)
RU (1) RU2007132980A (no)
TN (1) TNSN07304A1 (no)
TW (1) TW200640487A (no)
WO (1) WO2006082052A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595960A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
BRPI0918670B8 (pt) * 2008-09-17 2021-05-25 Xencor Inc anticorpo
CA2784498A1 (en) * 2009-12-18 2011-06-23 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10947320B2 (en) 2015-12-18 2021-03-16 University Of Notre Dame Du Lac Covalent heterobivalent antibody inhibitors and ligands
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR053541A1 (es) 2007-05-09
GT200600023A (es) 2006-08-16
CA2595976A1 (en) 2006-08-10
MA29273B1 (fr) 2008-02-01
PE20061203A1 (es) 2006-12-19
JP2008528650A (ja) 2008-07-31
IL184713A0 (en) 2007-12-03
AU2006210098A1 (en) 2006-08-10
TNSN07304A1 (en) 2008-12-31
RU2007132980A (ru) 2009-03-10
CN101111265A (zh) 2008-01-23
WO2006082052A1 (en) 2006-08-10
EP1846031A1 (en) 2007-10-24
GB0502358D0 (en) 2005-03-16
KR20070100344A (ko) 2007-10-10
MX2007009436A (es) 2007-08-17
US20080206237A1 (en) 2008-08-28
TW200640487A (en) 2006-12-01
BRPI0607349A2 (pt) 2009-09-01

Similar Documents

Publication Publication Date Title
NO20074497L (no) Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel
CY1114594T1 (el) Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη
TW200700406A (en) Novel thiophene derivatives
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
TW200716591A (en) Novel thiophene derivatives
NO20084882L (no) Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on
ZA200807274B (en) Novel pyridine derivatives
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
NO20083104L (no) Fast preparat
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
TW200738670A (en) Novel thiophene derivatives
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
WO2007016285A3 (en) M-csf specific monoclonal antibody and uses thereof
ATE513555T1 (de) Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
EP1827446A4 (en) SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND URETINS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS WITH ARENA VIRUSES
WO2004029214A8 (en) Lfa-1 alpha subunit antibodies and methods of use
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
JP2006527741A5 (no)
DE102006035083A8 (de) Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
任秀珍 et al. A Study of Stereotypes in Intercultural Communication

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application